Abstract
It is now almost 10 years since bovine spongiform encephalopathy (BSE) was first recognized, and considerable effort has been made to answer questions raised by its unexpected and undesirable appearance (1, 2). Epidemiologic studies have confirmed that BSE on a large-scale is found exclusively in adult cattle of the United Kingdom, while rare cases have been confirmed in indigenous cattle of very few other European nations. The disease has also appeared sporadically in cattle exported from the United Kingdom to other countries in Europe and elsewhere. The probable cause of the outbreak in the United Kingdom has been associated with significant changes in the manufacturing procedures used to prepare the meat and bone meal subsequently fed to cattle (3).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Wells GAH, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987;121:419–420.
Wilesmith JW, Wells GAH, Cranwell JP, Ryan JBM. Bovine spongiform encephalopathy: epidemiological studies. Vet Rec 1988;123:638–644.
Kimberlin RH, Wilesmith JW. Bovine spongiform encephalopathy. Epidemiology, low dose exposure and risks. Ann NY Acad Sci 1994;724:210–220.
Dealler SF, Lacey RW. Transmissible spongiform encephalopathies: the threat of BSE to man. Food Microbiol 1990;7:253–279.
Coyle E, Harvey I. Bovine spongiform encephalopathy and risk to health. Br Med J 1992;304:1509.
Ridley RM, Baker HF. Occupational risk of Creutzfeldt-Jakob disease. Lancet 1993;341:641–642.
Kaaden OR. Unconventionelle erreger—eine gefahr fur mensch und tier? Berl Munch Tierarztl Wochenschr 1994;107:44–48.
Goldberg H, Alter M, Kahana E. The Libyan Jewish focus of Creutzfeldt-Jakob disease: a search for the mode of natural transmission. In: Prusiner SB, Hadlow WJ, eds. Slow transmissible diseases of the nervous system, vol 1. New York: Academic Press, 1979:451–460.
Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. Creutzfeldt-Jakob disease: patterns of world-wide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177–188.
Davainpour Z, Alter M, Sobel E, Callahan M. Sheep consumption: a possible source of spongiform encephalopathy in humans. Neuroepidemiology 1985; 4:240–249.
Brown P, Cathala F, Raubertras RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987;37:895–904.
Cousens SN, Harries-Jones R, Knight R, Will RG, Smith PG, Matthews WB. Geographical distribution of cases of Creutzfeldt-Jakob disease in England and Wales 1970–84. J Neurol Neurosurg Psychiatry 1990;53:459–465.
Alperovitch A, Brown P, Weber T, Pocchiari M, Hofman A, Will RG. Incidence of Creutzfeldt-Jakob disease in Europe in 1993. Lancet 1994; 343:918.
Wilesmith JW, Ryan JBM. Bovine spongiform encephalopathy: observation of the incidence during 1992. Vet Rec 1993;132:300–301.
Hoinville LJ. Decline in the incidence of BSE in cattle born after the introduction of the “feed ban”. Vet Rec 1994;134:274–275.
Gajdusek DC. Spontaneous generation of infectious nucleating amyloids in the transmissible and nontransmissible cerebral amyloidoses. Mol Neurobiol 1994;8:1–13.
Hope J. The nature of the scrapie agent: the evolution of the virino. Ann NY Acad Sci 1994;724:282–289.
Pocchiari M. Prions and related neurological diseases. Mol Aspects Med 1994;15:195–291.
Prusiner SB, Hsiao KK. Human prion diseases. Ann Neurol 1994;35:385–395.
Kirkwood JK, Wells GAH, Wilesmith JW, Cunningham AA, Jackson SI. Spongiform encephalopathy in an Arabian oryx (Oryx leucoryx) and a greater kudu (Tragelaphus strepsiceros). Vet Rec 1990;127:418–420.
Wyatt JM, Pearson GR, Smerdon TN, Gruffydd Jones TJ, Wells GAH, Wilesmith JW. Naturally occurring scrapie-like spongiform encephalopathy in five domestic cats. Vet Rec 1991;129:233–236.
Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 1985;313:728–731.
Brown P, Preece MA, Will RG. “Friendly fire” in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992;340:24–27.
Gibbs CJ Jr, Asher DM, Brown P, Fradkin JE, Gajdusek DC. Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands. N Engl J Med 1993;328:358–359.
Minor P. Bovine spongiform encephalopathy and biological products for human use. Biologicals 1990;18:77–80.
Baron H. Bovine spongiform encephalopathy and related agents: risk factors of biological products. An informal consultation/working meeting. Toxicol Pathol 1991;19:293–297.
Di Martino A. Transmissible spongiform encephalopathies and the safety of naturally-derived biologicals. Biologicals 1993;21:61–66.
MacDiarmid SC. Risk analysis and the importation of animals and animal products. Rev Sci Tech 1993;12:1093–1107.
Bleem AM, Crom RL, Francy DB, Hueston WD, Kopral C, Walker KD. Risk factors and surveillance for bovine spongiform encephalopathy in the United States. J Am Vet Med Assoc 1994;204:644–651.
Schudel AA, Carrillo BJ, Gimeno EJ, et al. Bovine spongiform encephalopathy surveillance in Argentina. Rev Sci Tech 1994;13:801–836.
Millson GC, Hunter GD, Kimberlin RH. The physicochemical nature of the scrapie-agent. In: Kimberlin RH, ed. Slow virus diseases of animals and man. Amsterdam: North Holland, 1976:243–266.
Dickinson AG, Taylor DM. Resistance of scrapie agent to decontamination. N Engl J Med 1978;229:1413–1414.
Gibbs CJ Jr, Gajdusek DC, Latarjet R. Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt-Jakob disease and scrapie. Proc Natl Acad Sci USA 1978;75:6268–6270.
Millson GC, Manning EJ. The effect of selected detergents on scrapie infectivity. In: Prusiner SB, Hadlow WJ, eds. Slow transmissible diseases of the nervous system, vol 2. New York: Academic Press, 1979:409–424.
Prusiner SB, Groth DF, McKinley MP, Cochran SP, Bowman KA, Casper KC. Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc Natl Acad Sci USA 1981;78:4606–4610.
Bellinger-Kawahara CG, Diener TO, McKinley MP, Groth DF, Smith DT, Prusiner SB. Purified prions resist inactivation by procedures that hydrolyze, modify or shear nucleic acids. Virology 1987;160:271–274.
Ernst DR, Race RE. Comparative analysis of scrapie agent inactivation methods. J Virol Methods 1993;41:193–201.
Department of Health and Social Security. The management of patients with spongiform encephalopathy (Creutzfeldt-Jakob disease). DHSS Circular 16, 1984.
Rosenberg RN, White CL III, Brown P, et al. Precautions in handling tissues, fluids, and other contaminated material from patients with documented or suspected Creutzfeldt-Jakob disease. Ann Neurol 1986;19:75–77.
Kimberlin RH, Walker CA. Transport, targeting and replication of scrapie in CNS. In: Court LA, Dormont D, Brown P, Kingsbury DT, eds. Unconventional virus diseases of the central nervous system. Fontenay-aux-Roses, France: Commissariat à l’Énergie Atomique, 1989:547–562.
Di Martino A. Attempts to detect evidence of scrapie-associated protein in bovine tissue-derived products. J Am Vet Med Assoc 1990;196:1685–1686.
Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal cord injury. A randomized, placebo-controlled trial with GM1 ganglioside. N Engl J Med 1991;324:1829–1838.
Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, Di Stefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992;256:843–846.
Ariga T, Sekine M, Yu RK, Miyatake T. Disialogangliosides in bovine adrenal medulla. J Biol Chem 1982;257:2230–2235.
Ledeen RW, Yu RK. Gangliosides: structure, isolation and analysis. Meth Enzymol 1982;83:139–191.
Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Biologicals 1991;19:247–251.
Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines. EEC regulatory document. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing bovine spongiform encephalopathy via medicinal products. Biologicals 1992;20:155–158.
Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6M urea treatment of human growth hormone minimizes risk from potential CJD contamination. Horm Res 1991;35:161–166.
Pocchiari M. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses. Dev Biol Stand 1991;75:87–95.
Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27:493–497.
Safar J, Ceroni M, Piccardo P, Gajdusek DC, Gibbs CJ Jr. Scrapie-associated precursor proteins: antigenic relationship between species and immunochemical localization in normal, scrapie and Creutzfeldt-Jakob disease brain. Neurology 1990;40:513–517.
Di Martino A, Safar J, Ceroni M, Gibbs CJ Jr. Purification of non-infectious gangliosides from scrapie-infected hamster brains. Arch Virol 1992;124:111–121.
Di Martino A, Safar J, Ceroni M, Gibbs C, Jr. Inactivation of the scrapie agent in a scaled-down procedure for the purification of gangliosides from brain tissue. Dev Biol Stand 1993;80:187–194.
Di Martino A, Safar J, Gibbs CJ Jr. The consistent use of organic solvents for purification of phospholipids from brain tissue effectively removes scrapie infectivity. Biologicals 1994;22:221–225.
Fraser H, Bruce ME, Chree A, McConnell I, Wells GAH. Transmission of bovine spongiform encephalopathy and scrapie to mice. J Gen Virol 1992; 73:1891–1897.
Taylor DM, Fraser H, McConnell I, et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol 1994; 139:313–326.
Brown P, Rohwer RG, Gajdusek DC. Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue. J Infect Dis 1986; 153:1145–1148.
Safar J, Ceroni M, Piccardo P, et al. Subcellular distribution and physicochemical properties of scrapie-associated precursor protein and relationship with the scrapie agent. Neurology 1990;40:503–508.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Di Martino, A. (1996). Elimination of Scrapie-Agent Infectivity in Naturally Derived Biologics. In: Gibbs, C.J. (eds) Bovine Spongiform Encephalopathy. Serono Symposia USA Norwell, Massachusetts. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2406-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2406-8_24
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7527-5
Online ISBN: 978-1-4612-2406-8
eBook Packages: Springer Book Archive